This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe
10 - 12 June, 2025
Congress CenterBasel Switzerland

ATUM

Profile

Attached is our company logo and below is our profile:

ATUM (formerly DNA2.0) offers an integrated pipeline of solutions including gene design, optimization and synthesis, technology platforms for protein and strain engineering, and mammalian protein production and cell line development. ATUM explores novel applications of modern machine learning in combination with industrial scale gene synthesis for mega dimensional optimization of biological systems to industrialize biotechnology. The tools and technologies developed by ATUM are directly applicable to the pharmaceutical industry (e.g. protein pharmaceuticals, vaccines, gene therapy), agrochemical industry, diagnostics, food industry, and R&D throughout the life sciences. ATUM’s tools and solutions are fuelling the transformation of biology from a discovery science to an engineering discipline. The company is privately held and is headquartered in Newark, Calif. Visit http://www.atum.bio for more info.

We're bringing you

  • Engineering mAb-Like Molecules from Leads to Drugs

    13:30